Clinical trial · Observational
Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients
Clinical Trials to Evaluate the Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients With Non-small Cell Lung Cancer
NCT05450081CI-TRIAL-00072581completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our study aimed to evaluate the correlation between test reagent specific gene test results and the efficacy of relevant targeted drugs in patients with non-small cell lung cancer, and to support the continued registration of test reagents.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- PFS
- timeFrame
- October 2022-December 2022
- description
- Progression free survival time
- measure
- ORR
- timeFrame
- October 2022-December 2022
- description
- Objective response rate
- measure
- Consistency
- timeFrame
- October 2022-December 2022
- description
- he consistency of efficacy between specified kit and 22C3
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1)≥18，advanced non-small cell lung cancer confirmed by histopathology, and were previously or currently treated with gefitinib tablets (as the first-line treatment) or osimertinib (first-generation TKI resistance treatment) or crizotinib capsules monotherapy were evaluated for efficacy. * 2\) Able to provide FFPE samples with a storage life of 5 years: Large specimen 5 pieces in each case; 10 puncture specimens in each case Exclusion Criteria: * 1\) Pathological evaluation of the tissue sample has too few tumor cells (total number of tumor cells \>20%); * 2\) Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs; * 3\) Maintenance treatment when the disease does not progress after other anti-tumor treatments.
References
Publications (0)
Data not yet available
No reference posted for this study.